FDA Warning Letter to Empower Pharmacy: What It Says and Why It Matters
Bottom line
On September 18, 2026, the FDA sent a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy in Houston, Texas — one of the largest compounding pharmacies in the United States. The letter alleges that Empower mass-produced compounded versions of the GLP-1 drugs tirzepatide and semaglutide (with added vitamins) that were essentially copies of FDA-approved products, which federal law does not allow traditional compounding pharmacies to make at scale. It also cites insanitary conditions and sterile-manufacturing violations. A warning letter is not a shutdown order or a court ruling — it is the FDA's formal notice of alleged violations, giving the company 15 working days to respond. Empower has said it already fixed many of the cited issues and will cooperate with the agency.
SOURCE NOTE: The full text of the September 18, 2026 warning letter (No. 738238) is published on FDA.gov at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 (verified live Oct 12, 2026). This post was built from detailed secondary reporting that quotes and describes the letter — including legal analyses from Mondaq and Lengea Law, and reporting from Becker's Hospital Review and BioSpace — cross-checked across multiple independent outlets. Where only secondary sources were available, that is noted.
What happened
Warning Letter No. 738238 followed an FDA inspection of Empower's Houston facility from November 3 to 14, 2025. At the end of that inspection, investigators issued a Form FDA 483 listing their observations, and Empower submitted written responses in December 2025, March 2026, and April 2026. The FDA acknowledged those responses but concluded that violations remained, and issued the warning letter nearly a year after the inspection.
The letter was dated September 18, 2026 and published on September 22, 2026.
Detailed legal analysis of the letter:
What a warning letter is — and isn't
An FDA warning letter is the agency's way of formally notifying a company that it believes federal law has been violated, and giving the company a chance to correct the problems. It is not a final agency action, not a court judgment, and not an order to stop operating. The allegations in the letter are the FDA's enforcement position based on the records its investigators described — they have not been tested in court, and the recipient has the right to respond and disagree.
What the letter does carry is a clear threat: if the violations are not adequately addressed, the FDA says it may take legal action without further notice, including product seizure and court injunctions.
What the FDA alleged, part 1: mass-produced copies
The core allegation concerns two products: tirzepatide combined with niacinamide (a form of vitamin B3), and semaglutide combined with cyanocobalamin (vitamin B12). The FDA said these appeared to be "essentially copies" of FDA-approved products — the brand-name drugs Mounjaro/Zepbound (tirzepatide) and Ozempic/Wegovy (semaglutide) — compounded "regularly or in inordinate amounts."
Why that matters requires a short legal detour. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy is exempt from FDA premarket approval and certain manufacturing requirements, but only if it meets specific conditions. One condition: it may not regularly compound, or compound in inordinate amounts, drugs that are essentially copies of commercially available products. There is an exception — a compounded drug is not an "essentially copy" if a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner.
The FDA's position, in short: adding a vitamin does not by itself create a significant difference, and Empower's production volumes suggested the claimed differences were not real. Quoting the letter: "the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual."
Three specific documentation problems were cited, according to reporting on the letter:
Some prescriptions lacked any prescriber determination of significant difference.
Other prescriptions contained significant-difference statements repeated verbatim across many records, which the FDA suggested may have been pre-generated for prescribers to select.
Prescriptions were generated through third-party technology platforms offering pre-selected menu options for significant-difference statements, which the FDA said calls "the individualized nature of those determinations into question."
Because the products allegedly failed to meet Section 503A conditions, the FDA said they lost their exemptions — making them, in the agency's characterization, unapproved new drugs and misbranded drugs subject to the full approval, labeling, and manufacturing requirements of federal law.
Reporting on the letter's 503A findings:
What the FDA alleged, part 2: sterility and manufacturing
Separately from the copying allegations, the letter cited insanitary conditions and violations of current good manufacturing practice (CGMP). These included:
Failure to perform adequate smoke studies under dynamic conditions to confirm proper airflow in sterile processing areas.
Media fills (simulations used to validate aseptic technique) that were not performed under the most challenging or stressful conditions.
Deficiencies in aseptic processing, environmental monitoring, equipment maintenance, procedures to prevent microbiological contamination, written production controls, and quality-unit oversight.
The FDA also reviewed Empower's corrective actions and found the record mixed: some appeared adequate, others could not be fully evaluated, and the media-fill corrections were found deficient — with gaps including unsupported vial counts, unexplained entries, and data transcribed onto new forms without a clear audit trail.
Reporting on the sterility findings:
What the FDA asked Empower to do
The letter directed Empower to respond in writing within 15 working days, describing the specific steps taken to address each violation and prevent recurrence, with supporting documentation. It warned that failure to adequately address the matter may result in legal action, including seizure and injunction, without further notice.
As of this writing, no public reporting indicates whether Empower filed its response or whether the FDA has taken further enforcement action. The 15-working-day window from the letter's receipt would have closed in early October 2026.
How Empower responded
In a statement to reporters, Empower spokesperson Emma Neal said the company had "already remediated many of the issues outlined in the Warning Letter" and looked forward to working with the FDA on the remaining matters. She noted that Empower has been registered with the FDA for more than a decade, described regulatory oversight as essential to safe compounding, and said the company would continue working cooperatively with the agency to ensure patient access to quality compounded drug products.
Separately, Eli Lilly is suing Empower, alleging that the pharmacy's marketing of "personalized" products is deceptive and that it is mass-manufacturing standardized copies of Lilly's approved medicines. Empower disputes those claims, and the litigation is ongoing.
Empower's statement, via KING 5 reporting:
Why this letter matters beyond one pharmacy
This is not Empower's first warning letter. The FDA issued warning letters to Empower facilities in 2017 and 2021, and two more in April 2025 (Warning Letter Nos. 700962 and 700964), before this September 2026 letter. The earlier April 2025 letters are posted on fda.gov:
The broader context is the FDA's tightening posture on compounded GLP-1 drugs since the shortages ended:
The FDA removed tirzepatide from its drug shortage list in October 2024 and semaglutide in February 2025. Once shortages end, the legal basis for compounding copies of those drugs narrows sharply.
In February 2026, the FDA issued 30 warning letters to telehealth companies over marketing that implied compounded GLP-1 products were FDA-approved or equivalent to brand-name drugs.
In an April 2026 statement on GLP-1 compounding, the FDA said a semaglutide-plus-vitamin-B12 product is still essentially a copy when the amounts are within 10 percent of the approved products' strengths — and that it does not intend to take action against a pharmacy filling four or fewer such prescriptions per month.
The agency has reported receiving more than 1,700 adverse events associated with compounded semaglutide and tirzepatide as of May 2026.
The Empower letter is the clearest signal yet of how the FDA intends to draw the line between legitimate patient-specific compounding and mass production wearing a compounding label. Industry reaction has been split: patient-safety advocates called the letter overdue, while compounding trade groups argue that volume alone is not the violation and that the law sets no numerical cap on legitimate compounding.
For background on how unapproved weight-loss peptides reach patients outside regulated channels, see our reporting: https://www.thepeptidesplace.com/post/gray-market-retatrutide-injuries-tga-lab-tests and our legality guide: https://www.thepeptidesplace.com/post/are-peptides-legal-the-2026-federal-and-state-law-guide
FAQ
Does this warning letter mean compounded GLP-1 drugs are now illegal?
No. The letter targets one company's specific products and practices, not all compounded GLP-1 drugs. Compounding pharmacies may still compound GLP-1 products when they meet the legal conditions — for example, for an identified patient with a documented, prescriber-determined significant difference from the approved product. What the letter signals is that the FDA is now actively policing where the line sits.
Did the FDA shut down Empower Pharmacy?
No. A warning letter is not a shutdown order, a product seizure, or a court injunction. It is a formal notice of alleged violations with a demand for corrective action. The FDA warned that seizure or injunction could follow if the violations are not adequately addressed, but as of this writing no such action has been publicly reported.
I get a compounded GLP-1 from a pharmacy. Should I be worried?
This post cannot answer that for any individual — it is educational, not medical advice. What the letter underscores is a fact worth knowing: compounded drugs are not FDA-approved, and the FDA does not review their safety, quality, or effectiveness before they reach patients. If you take a compounded medication, the FDA's consistent advice is to discuss it with your prescriber and pharmacist, and to report any adverse events.
What does "essentially a copy" mean in plain language?
It means the compounded product is so close to an FDA-approved, commercially available drug that the law treats it as a duplicate rather than a customized medication. Under Section 503A, a compounding pharmacy cannot regularly make such copies in large amounts. Adding an ingredient like a vitamin does not automatically make the product different enough — the prescriber must determine that the change produces a significant difference for that specific patient.
Educational content only. This post is not medical or legal advice. It summarizes public reporting on an FDA enforcement action; the allegations described are the FDA's position and are subject to Empower Pharmacy's response.
Comments